Biotest AG

As of March 31, 2025, Biotest AG has 39.57M shares outstanding.

As of March 31, 2025, Biotest AG trades at a trailing price-to-earnings ratio of 71.37. The price-to-sales ratio is 2.49, and the price-to-book ratio stands at 5.41.

As of March 31, 2025, Biotest AG trades at an EV/EBITDA multiple of 139.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 139.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biotest AG trades at an EV/FCF ratio of 33.23, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2025, Biotest AG maintains a current ratio of 4.93, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2025, Biotest AG posted a negative return on equity (ROE) of -8.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.71, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 34.21, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.01 indicates how many times Biotest AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended March 31, 2025. That works out to an effective tax rate of 323.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on May 13, 2026, Biotest AG's stock has declined approximately 6.54% over the past 52 weeks. The 50-day moving average sits at 39.34, while the 200-day moving average is 40.21.

Over the twelve months ended March 31, 2025, Biotest AG posted a gross margin of 23.19, reflecting its pricing power and cost economics. The operating margin of 1.72 and net profit margin of -3.86 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield stands at 0.91, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Biotest AG shareholders.

Biotest AG's most recent stock split took place on July 15, 2015 with a 1:3 split ratio.

As of March 31, 2025, Biotest AG has an Altman Z-Score of 2.32, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.